Across TCGA pan-cancer cohorts, DEFB107A RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated DEFB107A data layer compared with 1 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DEFB107A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEFB107A expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

STAD and ESCA are the cancer types where DEFB107A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	IV	0.083	0.379	.001	63	view →
ESCA	DFS	Tertile	III,IV	0.850	0.282	.018	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: DEFB107A tumor-vs-normal RNA expression · all DEFB107A data types